

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Anna M. Kauppi et al.

Allowed: November 15, 2007

Application No.: 10/526,461

Confirmation No.: 3098

Filed: October 27, 2005

Art Unit: 1657

For: METHOD AND PROBE FOR IDENTIFYING
BACTERIAL VIRULENCE MODIFYING
AGENTS, AGENTS THUS IDENTIFIED, AND
THEIR USE

Examiner: B. Shen

REQUEST FOR SUPPLEMENTAL NOTICE OF ALLOWANCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Attn: MS Issue Fee

Dear Sir:

Applicants received a Notice of Allowance dated November 15, 007.

On March 3, 2005, Applicants filed an Information Disclosure Statements in the U.S. Patent Office. During final review of the allowed application, Applicants note that the Information Disclosure Statement of March 3, 2005 was not acknowledged.

Applicants respectfully request that the Information Disclosure Statement dated March 3, 2005 be acknowledged and considered for the above-referenced patent application, before payment of the issue fee. A copy of the Information Disclosure Statement, SB 0/8 (Form PTO-1449), (plus stamped postcard indicating receipt by the U.S. Patent Office) are enclosed for your convenience.

Application No.: 10/526,461

Docket No.: C2432.0061
(PATENT)

Please charge any credits or deficiencies to our Deposit Account No. 50-2215.

Dated: December 7, 2007

Respectfully submitted,

By 
Edward A. Meilman

Registration No.: 24,735
DICKSTEIN SHAPIRO LLP
1177 Avenue of the Americas
New York, New York 10036-2714
(212) 277-6500
Attorney for Applicant

Atty Docket No.: C2432.0061

Inventor: Anna M. Kauppi et al.

Application No.: Not Yet Assigned Filing Date: Concurrently Herewith
Title: METHOD AND PROBE FOR IDENTIFYING BACTERIAL VIRULENCE
MODIFYING AGENTS, AGENTS THUS IDENTIFIED, AND THEIR USE

Documents Filed:

Payment by credit card. Form PTO-2038 is attached (1 page)	Unsigned Oath or Declaration of the Inventors
Charge \$650.00 to credit card	IDS (2 pages) & PTO-SB/08 (2 pages) & International Search Report (4 pages) & International Preliminary Examination Report (18 pages)
Transmittal Letter to the United States Designated-Elected Office (2 pages)	PCT Request (7 pages)
First Preliminary Amendment (13 pages)	PCT/IB/308 (1 page)

Copy of International Application
WO 2004/022775 A1

DT07 Rec'd PCT/PTO 3 MAR 2005

10/526461

Via: PTO Daily Run

Sender's Initials: EAM/da

Date: March 3, 2005

Docket No.: C2432.0061
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Anna M. Kauppi et al.

Application No.: Not Yet Assigned

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: METHOD AND PROBE FOR
IDENTIFYING BACTERIAL
VIRULENCE MODIFYING AGENTS,
AGENTS THUS IDENTIFIED, AND
THEIR USE

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Timing of Filing of the Information Disclosure Statement:

☒ This IDS is being filed before the First Office Action¹.

¹ The IDS should, where possible, include a certification under 37 C.F.R. §1.97(c).

Copies of Information:

☒ Copies of the cited ISR documents are not enclosed as they were provided by the International Bureau.

Materiality:

Whether or not the information and references disclosed in this Information Disclosure Statement is "material" pursuant to 37 CFR 1.56, this submission is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

In the event the actual fee is inadvertently not enclosed or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge the underpayment to Deposit Account No. 50-2215.

Dated: March 3, 2005

Respectfully submitted,

By 
Edward A. Meilman

Registration No.: 24,735
DICKSTEIN SHAPIRO MORIN &
OSHINSKY LLP
1177 Avenue of the Americas
New York, New York 10036-2714
(212) 835-1400
Attorney for Applicant

EAM/da

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	Not Yet Assigned	
			Filing Date	Concurrently Herewith	
			First Named Inventor	Anna M. Kauppi	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	C2432.0061

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-6,136,541	10-24-2000	Brigitte Demers, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	GB-2,365,426-A	02-20-2002	PANTHERIX LTD		
	BB	WO-02/043668-A2	06-06-2002	WELLESLEY COLLEGE		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA	National Library of Medicine (NLM), file Medline, PMID: 8173809, Forsberg, A: "In vivo expression of virulence genes of Yersinia pseudotuberculosis"; Infect Agents Dis 1993 Aug; 2(4): 275-8		
	CB	ASM Abstract Database 2002 General Meeting (5/19/2002 through 5/23/2002) American Society for Microbiology, Vladimir Motin, et al.: "Genome-Wide Expressing Profiling of Yersinia pestis During Low-Calcium Response"; retrieved 4/4/2003 from http://www.asmsa.org/memonly/abstracts/AbstractView.asp?AbstractID=62023		
	CC	Infection and Immunity, Vol. 43(1); January 1984; Ingrid Bolin, et al.; "Molecular Cloning of the Temperature-Inducible Outer Membrane Protein 1 of Yersinia pseudotuberculosis"; page 72 - 78		
	CD	Molecular Microbiology, Vol. 2(2); 1988; Ingrid Bolin, et al.; "The plasmid-encoded Yop2b protein of Yersinia pseudotuberculosis is a virulence determinant regulated by calcium and temperature at the level of transcription"; page 237 - 245		
	CE	STN International, File CAPLUS, CAPLUS accession no. 1968:95469, Document no. 68:95469, Giuseppe Ciampa, et al.; "N-Substituted salicylamides. I. Halogenated 2-hydroxy- and 2-acetoxybenzanilides with antibacterial and antifungal activity"; Rendiconto dell'Accademia delle Scienze Fisiche e Matematiche, Naples 1966, 33(Dec.), 386-95		
	CF	STN International, File CAPLUS, CAPLUS accession no. 1978:94851, Document no. 88:94851, "Anthelmintic compositions based on benzimidazoles"; FR, A, 2336931, 19770729		
	CG	STN International, File CAPLUS, CAPLUS accession no. 1979:16910, Document no.: 90:16910, E.M. Shilakadze, et al.; "Antituberculosis activity of beta- and gamma-pyridinecarboxylic acid phenylhydrazones and their manganese(II) and manganese(III) complexes"; Soobshcheniya Akademii Nauk Gruzinskoi SSR (1978), 91(1), 145-8, esp. compound RN=68639-26-9		
	CH	STN International, File CAPLUS, CAPLUS accession no. 1992:645585, Document no. 117:245585, Ivanovo Agricultural Institute: "Method for treatment of fascioliasis and monieziaosis in sheep"; SU, A1, 1715357, 19920228		
Examiner Signature				Date Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Anna M. Kauppi
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	C2432.0061

CI	STN International, File CAPLUS, CAPLUS accession no. 1977:189559, Document no. 86:189559, Chinoi Gyogyszer es Vegyeszeti Termek Gyara Rt., Hung.: "Salicylanilides"; BE, A1, 839873, 19760716
CJ	STN International, File CAPLUS, CAPLUS accession no. 1985:487603, Document no.: 103:87603, J. M. Patel, et al.; "Studies on antitubercular and antibacterial agents: preparation of 1-(4-aminobenzoyl)-2-benzalhydrazine and 1-(4-(phenylthioureido)benzoyl)-2-substituted-benzalhydrazine"; Journal of the Indian Chemical Society; 1984; 61(8); 718-20
CK	STN International, File CAPLUS, CAPLUS accession no. 2002:298309, Document no. 137:169451, Vipin Kumar, et al.; "Synthesis and biological activities of 2-aryl-3-substituted benzamido-1,3-thiazolidin-4-ones" Indian Journal of Heterocyclic Chemistry; 2002; 11(13); 251-252
CL	J. Med. Chem.; Vol. 41, 1998, Mark J. Macielag, et al.; "Substituted Salicylanilides as Inhibitors of Two-Component Regulatory Systems in Bacteria"; page 2939 - 2945
CM	STN International, File CAPLUS, CAPLUS accession no. 2000:780229, Document no. 134:71527; Mazaahir, Kidwai, et al.; "Microwave assisted synthesis of new fungicidal pyrazoles"; Indian Journal of Chemistry; 2000; 39B(6); 458 - 461
CN	STN International, File CAPLUS, CAPLUS accession no. 2002:11847, Document no. 136:272653; K. Waisser, et al.; "2H-1,3-benzoxazine-2,4(3H)-diones substituted in position 6 as antimycobacterial agents"; Chemical Papers; 2001; 55(5); 323 - 334
CO	STN International, File CAPLUS, CAPLUS accession no. 1990:440580, Document no. 113:40580; R. P. Srivastava, et al.; "Synthesis of 2,5-disubstituted benzimidazoles, 1,3,4-thiadiazoles and 3,5-diiodosalicylanilides as structural congeners of rafoxanide and closantel"; Pharmazie (1990), 45(1), 34 - 7
CP	STN International, File CAPLUS, CAPLUS accession no. 1968:458923, Document no. 69:58923, Mario Covello, et al.; "New iodine containing organic compounds. Iodinated hydroxybenzanilides"; Rendiconto dell'Accademia delle Scienze Fisiche e Matematiche, Naples (1966), 33(Dec.), 309 - 18
CQ	STN International, File CAPLUS, CAPLUS accession no. 2000:72793, Document no. 132:202643, Eric W. Ainscough, et al.; "Cytotoxicity of salicylaldehyde benzoylhydrazone analogs and their transition metal complexes: quantitative structure-activity relationships"; Journal of Inorganic Biochemistry (1999), 77(3-4), 125-133
CR	STN International, File CAPLUS, CAPLUS accession no. 1999:184132, Document no. 130:204267, Michael Brandt, et al.; "MPL-receptor ligands, process for their preparation, medicaments containing them, and their use for the treatment and prevention of thrombocytopenia and anemia"; PCT Int. Appl., 42 pp.
CS	Database Registry; CAS RN:s 400054-03-7, 305338-58-3, 303084-13-1, 416883-56-2, and 341979-94-0.
CT	STN International, File CAPLUS, CAPLUS accession no. 1998:147346, Document no. 128:213381, Janet R. Fraser, et al.; "Compositions and methods for treating infections using analogs of indolicidin"; PCT Int. Appl., 130 pp.
CU	STN International, File CAPLUS, CAPLUS accession no. 1971:74914, Document no. 74:74914; A. P. Bekhli, et al.; "Synthesis of phenasal esters and their anthelmintic activity"; Meditsinskaya Parazitologiya i Parazitarnye Bolezni (1970), 39(5), 532-4

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--